XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

Product Information

Clinical data on plant-based oral solutions show non-invasive weight management can be effective and sustainable Blood lipid parameters, fasted glucose, and hemoglobin A1c (HbA1c) were assessed at visit 1 and visit 6.

Hunger Buddy must be taken as a whole capsule with a full glass of water (approximately 250ml). Do not open the capsule and avoid taking it in powder form to avoid choking.

Log in/register

This research confirms Redusure's role in appetite reduction by promoting pleasant feelings of fullness when taken before meals,' stated Holly Tully, VP of Marketing, InQpharm NA. 'The study also reveals just how effective these appetite-reducing properties are in helping individuals lose weight at a consistent, healthy rate.' Our findings stand in line with results obtained by Wang et al., who demonstrated that okra intake decreased serum and hepatic total cholesterol and triglyceride levels, and enhanced fecal excretion of bile acids in mice [ 46]. In other study, Kahlon et al. showed that okra polysaccharides have strong bile acid binding properties [ 47]. Furthermore, Chen et al. reported that okra powder showed oil-binding capacities and cholesterol adsorption properties [ 48]. Additionally, results from animal study by Han et al. imply that inulin may also possess a fat-binding property besides its known beneficial effect as prebiotic, which contributed to a lower triglyceride and cholesterol levels in rats fed with high fat diet in the experiments [ 49]. Thus, the cholesterol-lowering effect of IQP-AE-103 could possibly be related to the physicochemical properties of both okra and inulin.

There were statistically significant differences in reduction of body fat mass between the study groups at the end of the study (IQP-AE-103 high dose, vs. placebo; low dose, vs. placebo and high dose vs. low dose, ). Reduction of fat-free mass was observed over time in all the three study groups; however, there were no significant differences between the study groups. As demonstrated by Zaluvida Group’s research and evidenced in InQpharm’s three bmiSMART products, efficacious, safe and easy to apply approaches to weight management do exist. They also allow adaption to individual dietary habits (such as preference for fatty foods or carbohydrate-rich diets) and can help to overcome initial hunger sensations while individuals are transitioning to a healthier diet. The mean reduction in waist circumference was more pronounced in both IQP-AE-103 groups, compared with that in the placebo group at the end of the study. Subjects in the high-dose IQP-AE-103 arm had a mean reduction in waist circumference of 4.1 ± 3.3 cm, whereas the mean reduction in the low-dose IQP-AE-103 arm was 2.5 ± 2.4 cm, in contrast to only 0.9 ± 1.6 cm reported in the placebo group ( and versus placebo, respectively). Also, there were statistically significant differences in the percentage of subjects with reduction in hip circumference between the study groups at week 12, between high-dose IQP-AE-103 and the placebo group (91.4% vs. 54.8%; ), as well as between low-dose IQP-AE-103 and placebo groups (80% vs. 54.8%; ), however, not between low- and high-dose IQP-AE-103 groups ( ). No statistically significant differences in waist-to-hip ratio between the study groups were reported at week 12. Proprietary ingredient clinically shown to increase satiety and support significant weight loss in overweight and obese adults Do not take Hunger Buddy during pregnancy or whilst breastfeeding, or if your BMI (Body Mass Index) is below 18.5. It is recommended that you calculate your BMI before and during use.

The REDUSURE trademark was assigned an Application Number # 1756268 by the Canadian Intellectual Property Office (CIPO). B. Grube, et al., “IQP-VV-102, A Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety,” Evidence-Based Complementary and Alternative Medicine: http://dx.doi.org/10.1155/2015/413075 (2015). In our study, BMI, body fat mass, and waist and hip circumference were also found to be decreased significantly in both IQP-AE-103 dose groups. Lowering waist circumference, a marker of abdominal fat content, indicates that the treatment with IQP-AE-103 could potentially lower the risk of diabetes, coronary heart disease, and nonalcoholic fatty liver disease [ 42– 44]. Additionally, the changes in fat-free mass were not significantly different between the treatment groups, indicating that the weight loss effect was primarily due to body fat reduction. Unfortunately, although obesity stems from consuming more calories than the body burns, more than 80% of overweight and obese individuals have trouble losing and maintaining weight loss through diet and exercise alone. These individuals recognise the serious health consequences of being overweight and often undertake drastic measures, including drug therapies and invasive surgeries, to achieve a healthier weight. Non-invasive weight management solutions